Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAdvanced Health Vaginitis Testing Coverage | OpenP…
    Ask Trek AI about this page
    CurrentAdvanced HealthPolicy N/A

    Molecular Vaginitis Testing

    Customize your policy alerts

    Sign up for all advancedhealth policy alerts

    Know when advancedhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes medical necessity and appropriateness criteria for molecular nucleic acid amplification testing (NAAT) used to evaluate symptomatic vaginitis or vaginosis. It applies to providers and reviewers assessing coverage for molecular testing for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.

    Policy Summary
    PayerAdvanced Health
    PolicyMolecular Vaginitis Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument symptoms, specimen type, testing purpose, and diagnostic rationale when ordering molecular vaginitis testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Principal etiologies targeted
    ~90%Cases accounted for by principal etiologies
    95.3%-100%NAAT sensitivity for trichomoniasis
    5Explicitly non-covered use cases
    1 swab

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required specimen type

    Coverage Criteria

    Covered Indications

    Molecular vaginitis testing is medically necessary when ALL of the following are met.

    Covered indications

    • Symptomatic presentation: The patient has documented signs or symptoms consistent with vaginitis or vaginosis, such as abnormal vaginal discharge, odor, pruritus, irritation, dysuria, or dyspareunia.
    • Specimen requirement: The specimen is a single vaginal swab, either self-collected or clinician-collected.single vaginal swab

      Collection must be consistent with the manufacturer's FDA-cleared instructions.

    • Testing purpose: Testing is ordered to identify the cause among bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.3 principal etiologies

    • Diagnostic circumstances

      • Microscopy unavailable: In-office microscopy is unavailable.
      • Equivocal microscopy: In-office microscopy results are equivocal.
      • Failed empiric therapy: Empiric therapy has failed.

    Testing outside the manufacturer’s FDA-cleared age range is not covered. Examples include BD Max and Xpert Xpress MVP assays cleared for patients 18 years and older, and Aptima BV and Aptima CV/TV assays cleared for patients 14 years and older. Coverage should be evaluated against the specific assay’s FDA-cleared labeling.

    A stand-alone, single-organism assay targeting only Gardnerella vaginalis is not covered when used as the sole diagnosis of bacterial vaginosis. No single sentinel organism reliably identifies bacterial vaginosis.

    Molecular vaginitis testing is not medically necessary for asymptomatic screening, test-of-cure testing, confirmation of treatment response, or prognostic use. Repeat panel testing for the same clinical episode is also not covered unless there has been a change in clinical status.

    Covered Indications

    Evaluation of Patients With Documented Signs or Symptoms Consistent With Vaginitis or Vaginosis

    Covered for evaluation of patients with documented signs or symptoms consistent with vaginitis or vaginosis when ALL of the following are met.

    Evaluation requirements

    • Documented symptoms: Signs or symptoms consistent with vaginitis or vaginosis are documented in the medical record, including abnormal vaginal discharge, odor, pruritus, irritation, dysuria, or dyspareunia.
    • Specimen collection: A single vaginal swab is used for testing and is either self-collected by the patient or collected by a clinician.single vaginal swab

      Specimen collection must follow the manufacturer's FDA-cleared instructions.

    • Appropriate testing target:

    Provider Documentation and Review Actions

    Documentation Required

    Medical Necessity Review

    Before ordering molecular vaginitis testing, confirm and document that medical necessity criteria are met. Review the medical record, focused history, and physical examination, and ensure the test is being used for a symptomatic diagnostic evaluation rather than screening or another non-covered purpose.

    • Document signs or symptoms consistent with vaginitis or vaginosis, such as abnormal vaginal discharge, odor, pruritus, irritation, dysuria, or dyspareunia.
    • Confirm the specimen is a single vaginal swab, self-collected or clinician-collected, obtained according to the manufacturer's FDA-cleared instructions.
    • Order testing to identify the principal etiologies of vaginitis: bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
    • Use NAAT as an appropriate diagnostic step when in-office microscopy is unavailable, results are equivocal, or empiric therapy has failed; NAAT is the recommended method for diagnosing trichomoniasis.
    • Verify the test is performed within the manufacturer's FDA-cleared age range.
    Documentation Required

    Required Ordering Documentation

    Clinical Background

    Preferred first-line evaluation of symptomatic vaginitis remains a complete history and physical examination with clinic-based testing, including vaginal pH, KOH whiff testing, and saline and 10% KOH microscopy. For suspected bacterial vaginosis, Amsel criteria and Gram stain with Nugent scoring remain preferred reference methods. Multiplex NAAT panels may improve detection of mixed or co-infections and are particularly appropriate when microscopy is unavailable or equivocal, or when empiric therapy has failed. NAAT is the recommended diagnostic method for trichomoniasis because of its high sensitivity and specificity.

    Definitions

    Definitions
    Full termNucleic acid amplification test (NAAT)
    Clinical useMolecular testing used to evaluate vaginitis or vaginosis.
    Diagnostic roleAn appropriate diagnostic step when in-office microscopy is unavailable, equivocal, or empiric therapy has failed.
    TrichomoniasisThe recommended diagnostic method, with reported sensitivity of 95.3%-100% and specificity of 95.2%-100%.
    Principal etiologies of vaginitis
    Bacterial vaginosisA principal etiology addressed by molecular vaginitis testing.
    Vulvovaginal candidiasis

    Testing Frequency Limits

    Frequency limits
    TestMolecular vaginitis panel.
    EpisodeThe same clinical episode.
    Coverage ruleRepeat panel testing is not covered for the same episode.
    ExceptionRepeat testing may be covered when there is a change in clinical status.

    Ordering Requirements

    Documentation Required

    ORDERING REQUIREMENTS

    Before submitting the order, include presenting symptoms, relevant examination and/or point-of-care findings, the specific organisms or panel requested, and the rationale when in-office microscopy was not diagnostic. Chlamydia trachomatis and Neisseria gonorrhoeae co-testing should be guided by STI risk assessment.

    • Document presenting symptoms.
    • Record relevant examination or point-of-care findings.
    • Name the specific organisms or panel ordered.
    • Include the rationale when in-office microscopy was not diagnostic.

    Non-Covered Uses

    The following uses are not covered: molecular vaginitis panels for screening asymptomatic patients; test-of-cure or confirmation-of-treatment-response testing; prognostic testing; repeat panel testing for the same episode without a change in clinical status; testing outside the manufacturer’s FDA-cleared age range; and stand-alone single-organism Gardnerella vaginalis assays used to diagnose bacterial vaginosis.

    Policy Summary
    PayerAdvanced Health
    PolicyMolecular Vaginitis Testing
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument symptoms, specimen type, testing purpose, and diagnostic rationale when ordering molecular vaginitis testing.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsProvider Documentation and Review ActionsClinical BackgroundDefinitionsTesting Frequency LimitsOrdering RequirementsNon-Covered Uses
    The testing is intended to identify bacterial vaginosis, vulvovaginal candidiasis, and/or trichomoniasis.

  1. Appropriate diagnostic circumstance

    • Microscopy unavailable: In-office microscopy is unavailable.
    • Equivocal microscopy: In-office microscopy results are equivocal.
    • Failed empiric therapy: Empiric therapy has failed.

    2. The ordering record must contain enough clinical detail to support the specific molecular vaginitis test ordered and explain the diagnostic rationale. Document relevant history and examination findings, including point-of-care testing when performed.

    • Record the patient's presenting symptoms.
    • Document relevant examination findings and/or point-of-care findings, including microscopy results when available.
    • Identify the specific organisms or molecular panel ordered.
    • Document the rationale when in-office microscopy was unavailable, equivocal, or not diagnostic.
    • Guide co-testing for Chlamydia trachomatis and Neisseria gonorrhoeae by the patient's STI risk assessment.
    Denial Risk

    Non-Covered Testing Circumstances

    Molecular vaginitis testing is not covered and is not medically necessary when used for asymptomatic screening, treatment monitoring, prognostic purposes, or other excluded circumstances.

    • Screening asymptomatic patients; these panels are not validated or intended for screening.
    • Test of cure or confirmation of treatment response.
    • Prognostic use.
    • Repeat panel testing for the same episode without a change in clinical status.
    • Testing outside the manufacturer's FDA-cleared age range, including examples such as BD Max and Xpert Xpress MVP cleared for patients age 18 years and older and Aptima BV and CV/TV cleared for patients age 14 years and older.
    • Single-organism assays targeting only Gardnerella vaginalis as a stand-alone diagnosis of bacterial vaginosis, because no single sentinel organism reliably identifies bacterial vaginosis.
    A principal etiology addressed by molecular vaginitis testing.
    TrichomoniasisA principal etiology addressed by molecular vaginitis testing and the recommended indication for NAAT diagnosis.
    Clinical significanceThese three etiologies together account for approximately 90% of vaginitis cases and frequently co-occur.